Overview
Membranous glomerulonephritis (MG) is characterized by immune complex deposition leading to glomerular basement membrane thickening, often resulting in nephrotic syndrome 12. It can be primary or secondary to various underlying conditions 26.Diagnosis
Clinical Presentation: Nephrotic syndrome (heavy proteinuria, hypoalbuminemia, edema, hyperlipidemia) 1.
Serological Tests: Evaluate for underlying causes such as infections (e.g., hepatitis C), autoimmune diseases (e.g., sarcoidosis), and malignancies 26.
Imaging: Consider in cases with atypical presentations or complications (e.g., horseshoe kidney) 3.
Renal Biopsy: Essential for definitive diagnosis, showing characteristic basement membrane immune complex deposits 1346.
Complement Levels: Hypocomplementemia may indicate certain underlying conditions (e.g., cold activation of complement) 3.Management
First-Line Treatments:
- Corticosteroids: Often used as initial therapy 2.
- Immunosuppressive Agents: Such as cyclophosphamide or rituximab for refractory cases 2.
Adjunctive Treatments:
- Lipid Management: Statins for hyperlipidemia associated with nephrotic syndrome 1.
- Blood Pressure Control: ACE inhibitors or ARBs to reduce proteinuria and protect renal function 2.Special Populations
Pediatrics: Secondary MG is common; clinical, serological, and morphological analysis crucial for diagnosis 2.
Elderly: Increased likelihood of secondary MG; thorough evaluation for underlying causes essential 2.
Comorbidities:
- Sarcoidosis: MG can occur; monitor for renal vein thrombosis 6.
- Neurological Conditions: Chronic progressive demyelinating neuropathies may coexist 4.
Genetic Factors: Familial cases suggest genetic predisposition; consider HLA typing in familial clusters 5.Key Recommendations
Perform renal biopsy for definitive diagnosis of membranous glomerulonephritis (Evidence: Strong 1346).
Investigate underlying causes through clinical, serological, and morphological analysis, especially in secondary MG (Evidence: Strong 2).
Initiate corticosteroid therapy as first-line treatment for membranous glomerulonephritis, with consideration of immunosuppressive agents for refractory cases (Evidence: Moderate 2).
Manage hyperlipidemia aggressively with statins in patients with nephrotic syndrome (Evidence: Moderate 1).
Screen for and manage associated comorbidities, such as sarcoidosis and neurological conditions, given their potential impact on prognosis (Evidence: Moderate 46).References
1 Hartland AJ, Giles PD, Bridger JE, Simmons W. A case of membranous glomerulonephritis presenting as pulmonary embolism and acute hyperlipidaemia. Journal of clinical pathology 2002. link
2 Glassock RJ. Secondary membranous glomerulonephritis. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 1992. link
3 Fujimoto S, Hirayama N, Uchida T, Iemura F, Yamamoto Y, Eto T et al.. Horseshoe kidney and membranous glomerulonephritis with cold activation of complement. Internal medicine (Tokyo, Japan) 1992. link
4 Witte AS, Burke JF. Membranous glomerulonephritis associated with chronic progressive demyelinating neuropathy. Neurology 1987. link
5 Vasmant D, Murnaghan K, Bensman A, Muller JY, Mougenot B. Familial idiopathic membranous glomerulonephritis. The International journal of pediatric nephrology 1984. link
6 Mariani AF, Clifton S, Davies DJ, Dawborn JK, Fitzgerald JE, Ihle BU et al.. Membranous glomerulonephritis associated with sarcoidosis. Australian and New Zealand journal of medicine 1978. link